ArticleJournal for immunotherapy of cancer2026
Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03225365 (Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).
Who cites it
2 citing papers in PubMed.
- Melanoma cell states shape spatial tumor-immune ecosystems to dictate the efficacy of anti-PD1 immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Travelling Waves in Gene Expression: A Mathematical Model of Cell-State Dynamics in Melanoma.Bulletin of mathematical biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma shows one of the highest response rates to immune checkpoint inhibitors (ICIs), yet nearly half of patients experience primary or acquired resistance. While immune contexture strongly influences therapeutic efficacy, tumor cell-intrinsic features are increasingly recognized as key regulators of antitumor immunity. In particular, intratumoral heterogeneity driven by melanoma cell plasticity underlies diverse immune escape mechanisms. How this plasticity shapes ICI outcomes in patients remains poorly defined.
methodsTumor cell states and immune contexture were assessed in 57 primary cutaneous melanomas from stage III patients, collected prior to adjuvant anti-programmed cell death protein-1 (anti-PD-1) therapy and stratified according to 2-year relapse status (33 relapse-free, 24 relapsed). Whole slide multiplex immunofluorescence was combined with spatial transcriptomics (Visium, n=4) to investigate the spatial architecture of melanoma cell states, T cells, tumor-associated macrophages (TAMs), dendritic cell subsets, and tertiary lymphoid structures.
resultsUnsupervised clustering of melanoma cells identified distinct phenotypic states that formed spatially restricted homotypic patches. From these data, we defined a melanoma plasticity ratio (undifferentiated/differentiated tumor patches), which was significantly associated with reduced relapse-free survival. Integrated immune analyses recapitulated prognostically distinct immunotypes, with macrophage subsets displaying striking spatial compartmentalization. Antitumoral macrophages preferentially infiltrated differentiated melanoma regions, while protumoral macrophages localized to undifferentiated patches. Spatial transcriptomics confirmed that melanoma cell states tightly shape the neighboring immune microenvironment, with macrophages emerging as pivotal players. Their polarization was further influenced by tumor-derived signals in addition to microenvironmental cues (interferon-gamma, hypoxia). Entropy-based integration of melanoma cell states, TAMs, and T cell subsets uncovered two dominant spatial ecosystems with opposing associations to ICI efficacy. Ecosystems enriched in differentiated melanoma cells, programmed death-ligand 1 (PD-L1)
conclusionsOur study uncovers how cancer cell plasticity shapes spatially organized tumor-immune ecosystems that critically modulate adjuvant ICI efficacy in melanoma. These findings highlight melanoma cell plasticity as a key driver of immune evasion via macrophages reprogramming, through targetable interactions that may represent novel therapeutic avenues to enhance ICI efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.